Immunogenicity and reactogenicity of accelerated regimens of fractional intradermal COVID-19 vaccinations
IntroductionThis phase I study explored the immunogenicity and reactogenicity of accelerated, Q7 fractional, intradermal vaccination regimens for COVID-19.MethodsParticipants (n = 60) aged 18-60 years, naïve to SARS-CoV-2 infection or vaccination, were randomly allocated into one of four homologous...
| Main Authors: | , , , , , , , , |
|---|---|
| Format: | Article |
| Language: | English |
| Published: |
Frontiers Media S.A.
2023-01-01
|
| Series: | Frontiers in Immunology |
| Subjects: | |
| Online Access: | https://www.frontiersin.org/articles/10.3389/fimmu.2022.1080791/full |
| _version_ | 1797951433414279168 |
|---|---|
| author | Suvimol Niyomnaitham Suvimol Niyomnaitham Suparat Atakulreka Patimaporn Wongprompitak Katherine Kradangna Copeland Zheng Quan Toh Zheng Quan Toh Paul V. Licciardi Paul V. Licciardi Kanjana Srisutthisamphan Laddawan Jansarikit Kulkanya Chokephaibulkit Kulkanya Chokephaibulkit |
| author_facet | Suvimol Niyomnaitham Suvimol Niyomnaitham Suparat Atakulreka Patimaporn Wongprompitak Katherine Kradangna Copeland Zheng Quan Toh Zheng Quan Toh Paul V. Licciardi Paul V. Licciardi Kanjana Srisutthisamphan Laddawan Jansarikit Kulkanya Chokephaibulkit Kulkanya Chokephaibulkit |
| author_sort | Suvimol Niyomnaitham |
| collection | DOAJ |
| description | IntroductionThis phase I study explored the immunogenicity and reactogenicity of accelerated, Q7 fractional, intradermal vaccination regimens for COVID-19.MethodsParticipants (n = 60) aged 18-60 years, naïve to SARS-CoV-2 infection or vaccination, were randomly allocated into one of four homologous or heterologous accelerated two-dose, two-injection intradermal regimens seven days apart:(1) BNT162b2-BNT162b2(n= 20),(2) ChAdOx1- BNT162b2 (n = 20), (3) CoronaVac-ChAdOx1 (n = 10), and (4) ChAdOx1-ChAdOx1 (n = 10). CoronaVac and ChAdOx1 were 20%, and BNT162b2 17%, of their standard intramuscular doses (0.1 mL and 0.05 mL per injection, respectively). Humoral immune responses were measured through IgG response towards receptor binding domains (RBD-IgG) of ancestral SARS-CoV-2 spike protein and pseudovirus neutralization tests (PVNT50). Cellular immune responses were measured using ELISpot for ancestral protein pools.ResultsImmunogenicity was highest in regimen (2), followed by (1), (4), and (3) 2 weeks after the second dose (P < 0.001 for anti-RBD-IgG and P= 0.01 for PVNT50). Each group had significantly lower anti-RBD IgG (by factors of 5.4, 3.6, 11.6, and 2.0 for regimens (1) to (4), respectively) compared to their respective standard intramuscular regimens (P < 0.001 for each). Seroconversion rates for PVNT50 against the ancestral strain were 75%, 90%, 57% and 37% for regimens (1) to (4), respectively. All participants elicited ELISpot response to S-protein after vaccination. Adverse events were reportedly mild or moderate across cohorts.DiscussionWe concluded that accelerated, fractional, heterologous or homologous intradermal vaccination regimens of BNT162b2 and ChAdOx1 were well tolerated, provided rapid immune priming against SARS-CoV-2, and may prove useful for containing future outbreaks. |
| first_indexed | 2024-04-10T22:30:31Z |
| format | Article |
| id | doaj.art-35bdb0b5c2494c62bbd51d2dc73a2e2e |
| institution | Directory Open Access Journal |
| issn | 1664-3224 |
| language | English |
| last_indexed | 2024-04-10T22:30:31Z |
| publishDate | 2023-01-01 |
| publisher | Frontiers Media S.A. |
| record_format | Article |
| series | Frontiers in Immunology |
| spelling | doaj.art-35bdb0b5c2494c62bbd51d2dc73a2e2e2023-01-17T04:48:34ZengFrontiers Media S.A.Frontiers in Immunology1664-32242023-01-011310.3389/fimmu.2022.10807911080791Immunogenicity and reactogenicity of accelerated regimens of fractional intradermal COVID-19 vaccinationsSuvimol Niyomnaitham0Suvimol Niyomnaitham1Suparat Atakulreka2Patimaporn Wongprompitak3Katherine Kradangna Copeland4Zheng Quan Toh5Zheng Quan Toh6Paul V. Licciardi7Paul V. Licciardi8Kanjana Srisutthisamphan9Laddawan Jansarikit10Kulkanya Chokephaibulkit11Kulkanya Chokephaibulkit12Siriraj Institute of Clinical Research, Bangkok, ThailandDepartment of Pharmacology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, ThailandSiriraj Institute of Clinical Research, Bangkok, ThailandDepartment of Immunology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, ThailandDepartment of Biological Sciences, Faculty of Science, Mahidol University International College, Nakhon Pathom, ThailandInfection and Immunology, Murdoch Children’s Research Institute, Parkville, VIC, AustraliaDepartment of Pediatrics, The University of Melbourne, Parkville, VIC, AustraliaInfection and Immunology, Murdoch Children’s Research Institute, Parkville, VIC, AustraliaDepartment of Pediatrics, The University of Melbourne, Parkville, VIC, AustraliaNational Center for Genetic Engineering and Biotechnology (BIOTEC), National Science Development Agency (NSTDA), Pathumthani, ThailandDepartment of Pharmacology, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, ThailandSiriraj Institute of Clinical Research, Bangkok, ThailandDepartment of Pediatrics, Faculty of Medicine Siriraj Hospital, Mahidol University, Bangkok, ThailandIntroductionThis phase I study explored the immunogenicity and reactogenicity of accelerated, Q7 fractional, intradermal vaccination regimens for COVID-19.MethodsParticipants (n = 60) aged 18-60 years, naïve to SARS-CoV-2 infection or vaccination, were randomly allocated into one of four homologous or heterologous accelerated two-dose, two-injection intradermal regimens seven days apart:(1) BNT162b2-BNT162b2(n= 20),(2) ChAdOx1- BNT162b2 (n = 20), (3) CoronaVac-ChAdOx1 (n = 10), and (4) ChAdOx1-ChAdOx1 (n = 10). CoronaVac and ChAdOx1 were 20%, and BNT162b2 17%, of their standard intramuscular doses (0.1 mL and 0.05 mL per injection, respectively). Humoral immune responses were measured through IgG response towards receptor binding domains (RBD-IgG) of ancestral SARS-CoV-2 spike protein and pseudovirus neutralization tests (PVNT50). Cellular immune responses were measured using ELISpot for ancestral protein pools.ResultsImmunogenicity was highest in regimen (2), followed by (1), (4), and (3) 2 weeks after the second dose (P < 0.001 for anti-RBD-IgG and P= 0.01 for PVNT50). Each group had significantly lower anti-RBD IgG (by factors of 5.4, 3.6, 11.6, and 2.0 for regimens (1) to (4), respectively) compared to their respective standard intramuscular regimens (P < 0.001 for each). Seroconversion rates for PVNT50 against the ancestral strain were 75%, 90%, 57% and 37% for regimens (1) to (4), respectively. All participants elicited ELISpot response to S-protein after vaccination. Adverse events were reportedly mild or moderate across cohorts.DiscussionWe concluded that accelerated, fractional, heterologous or homologous intradermal vaccination regimens of BNT162b2 and ChAdOx1 were well tolerated, provided rapid immune priming against SARS-CoV-2, and may prove useful for containing future outbreaks.https://www.frontiersin.org/articles/10.3389/fimmu.2022.1080791/fullfractional doseintradermalaccelerated regimenCOVID-19 vaccinationimmunogenicityheterologous regimen |
| spellingShingle | Suvimol Niyomnaitham Suvimol Niyomnaitham Suparat Atakulreka Patimaporn Wongprompitak Katherine Kradangna Copeland Zheng Quan Toh Zheng Quan Toh Paul V. Licciardi Paul V. Licciardi Kanjana Srisutthisamphan Laddawan Jansarikit Kulkanya Chokephaibulkit Kulkanya Chokephaibulkit Immunogenicity and reactogenicity of accelerated regimens of fractional intradermal COVID-19 vaccinations Frontiers in Immunology fractional dose intradermal accelerated regimen COVID-19 vaccination immunogenicity heterologous regimen |
| title | Immunogenicity and reactogenicity of accelerated regimens of fractional intradermal COVID-19 vaccinations |
| title_full | Immunogenicity and reactogenicity of accelerated regimens of fractional intradermal COVID-19 vaccinations |
| title_fullStr | Immunogenicity and reactogenicity of accelerated regimens of fractional intradermal COVID-19 vaccinations |
| title_full_unstemmed | Immunogenicity and reactogenicity of accelerated regimens of fractional intradermal COVID-19 vaccinations |
| title_short | Immunogenicity and reactogenicity of accelerated regimens of fractional intradermal COVID-19 vaccinations |
| title_sort | immunogenicity and reactogenicity of accelerated regimens of fractional intradermal covid 19 vaccinations |
| topic | fractional dose intradermal accelerated regimen COVID-19 vaccination immunogenicity heterologous regimen |
| url | https://www.frontiersin.org/articles/10.3389/fimmu.2022.1080791/full |
| work_keys_str_mv | AT suvimolniyomnaitham immunogenicityandreactogenicityofacceleratedregimensoffractionalintradermalcovid19vaccinations AT suvimolniyomnaitham immunogenicityandreactogenicityofacceleratedregimensoffractionalintradermalcovid19vaccinations AT suparatatakulreka immunogenicityandreactogenicityofacceleratedregimensoffractionalintradermalcovid19vaccinations AT patimapornwongprompitak immunogenicityandreactogenicityofacceleratedregimensoffractionalintradermalcovid19vaccinations AT katherinekradangnacopeland immunogenicityandreactogenicityofacceleratedregimensoffractionalintradermalcovid19vaccinations AT zhengquantoh immunogenicityandreactogenicityofacceleratedregimensoffractionalintradermalcovid19vaccinations AT zhengquantoh immunogenicityandreactogenicityofacceleratedregimensoffractionalintradermalcovid19vaccinations AT paulvlicciardi immunogenicityandreactogenicityofacceleratedregimensoffractionalintradermalcovid19vaccinations AT paulvlicciardi immunogenicityandreactogenicityofacceleratedregimensoffractionalintradermalcovid19vaccinations AT kanjanasrisutthisamphan immunogenicityandreactogenicityofacceleratedregimensoffractionalintradermalcovid19vaccinations AT laddawanjansarikit immunogenicityandreactogenicityofacceleratedregimensoffractionalintradermalcovid19vaccinations AT kulkanyachokephaibulkit immunogenicityandreactogenicityofacceleratedregimensoffractionalintradermalcovid19vaccinations AT kulkanyachokephaibulkit immunogenicityandreactogenicityofacceleratedregimensoffractionalintradermalcovid19vaccinations |